Top 5 Drug Type | Count |
---|---|
Small molecule drug | 68 |
Monoclonal antibody | 16 |
Autologous CAR-T | 13 |
CAR-T | 6 |
Radiolabeled antibody | 5 |
Target |
Mechanism HIV-1 capsid inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date17 Aug 2022 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date25 Aug 2021 |
Target |
Mechanism JAK1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date24 Sep 2020 |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2024 |
Sponsor / Collaborator ![]() [+1] |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Axicabtagene Ciloleucel ( CD19 ) | Recurrent Follicular Lymphoma More | Approved |
Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate ( RT ) | HIV Infections More | Approved |
Remdesivir ( RdRp ) | COVID-19 More | Approved |
Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide Fumarate ( CYP3A x HIV-1 integrase x RT ) | HIV Infections More | Approved |
Tenofovir Alafenamide Fumarate ( RT ) | Hepatitis B, Chronic More | Approved |